Statistical challenges and opportunities in drug development – the Boehringer-Ingelheim perspective
报告人： Hans-Juergen Lomp, Boehringer Ingelheim
时间：2016-06-17 14:00 ~ 15:00
The application of statistics within medical science is regarded as one of the great medical breakthroughs in the last millennium (New England Journal of Medicine, 2000, 342:42-49). Accordingly pharmaceutical companies are among the largest producers of medical statistics. Despite the long history of medical statistics within drug development there are still methodological challenges. This include for instance increased focus on more efficient clinical development processes and on patient tailored treatment (i.e. personalized medicine). In this talk I discuss how Boehringer-Ingelheim works with statistics and the methodological challenges the company sees as well as present the role of the statistician in a large pharmaceutical company.
About the Speaker:
Hans-Juergen Lomp, Dipl. Math., has more than 25 years of pharma industry experience as a statistician. Worked 10 years for Hoechst, now Sanofi, as a project statistician in Diabetes and Cardiovascular, as well as a statistics manager. Changed to Boehringer Ingelheim (BI) to become Group Head Statistics, covering all statistical aspects from basic research, non-clinical development, pharma production development, as well as clinical development and medical affairs support. Chaired the statistics leader group of the VFA (Association of Germany’s researched based pharma companies) for several years. In 2013 has been appointed Global Head of Statistics for BI. Co-chaired the BI Transparency Initiative including clinical trial results disclosure and public access procedures to BI trial data.